Schlagwort -targeted- in den Versicherungs-News
Schlagwort -targeted- in den Versicherungs-News
2012-05-20 12:07:03
Woburn, Massachusetts And Tokyo (ots/PRNewswire) -
ArQule, Inc.
and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma (HCC). ArQule announced that this ...
2012-05-19 12:10:06
Woburn, Massachusetts And Tokyo (ots/PRNewswire) -
ArQule, Inc.
and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma (HCC). ArQule announced that this ...
2012-05-18 12:08:17
Woburn, Massachusetts And Tokyo (ots/PRNewswire) -
ArQule, Inc.
and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma (HCC). ArQule announced that this ...
Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
2012-05-18 12:08:10
Hatfield, England (ots/PRNewswire) -
Eisai announced today that 12 abstracts highlighting new study results will be presented during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, USA, from 1-5 June 2012.
These studies highlight Eisai's current product portfolio and oncology pipeline, reinforcing the company's commitment to patients and ...
2012-05-04 12:10:47
St Petersburg, Russland (ots/PRNewswire) -
St. Petersburg, Russische Föderation - 4-5. Mai 2012
Der Anbieter für kontinuierliche medizinische Fortbildung (Continuing Medical Education, CME) Serono Symposia International Foundation, der für die Initiative für medizinische Fortbildung im Bereich molekular orientierte Krebstherapie (Molecular Targeted Therapy of Cancer, MTTC) verantwortlich ...
2012-04-24 12:09:32
Rom (ots/PRNewswire) -
Ein völlig neues, zeitgemässes visuelles Design für neue Möglichkeiten
und Funktionen
Die medizinische Fortbildungsinitiative Molecular Targeted Therapy of Cancer (MTTC, zielgerichteten Molekulartherapie bei Krebs) hat eine neue Version ihrer Website zur hochwertigen medizinischen Weiterbildung medizinischer, chirurgischer und radiologischer Onkologen gestartet. ...
Pieris Presents Preclinical Data for PRS-110 c-Met Antagonist Anticalin® at the AACR Annual Meeting
2012-04-04 12:10:46
Chicago, Illinois (ots) -
--Results Support Differentiating Drug-like Features for Targeted Anti-cancer Drug--
Pieris AG announced today the presentation of a range of in vitro and in vivo preclinical data for the company's proprietary c-Met antagonist program, PRS-110, at the American Association for Cancer Research (AACR) Annual Meeting, further establishing the compound as a differentiated ...
2012-04-03 12:08:51
Nürnberg (ots) - Intelligent, progressive, application-based: The new Ziehm Imaging Internet site now offers customers and interested parties even faster access to company and product information. The entire product portfolio of the market and innovation leader for mobile C-arms is presented clearly in a brand-new look and supplemented by extensive background information on the application ...
Ethernet Europe Announces Colt as Host Sponsor
2012-04-03 12:04:11
Irvine, California (ots/PRNewswire) -
A Record Number of Operators on the Conference Agenda
Light Reading will host its seventh Ethernet Europe [http://www.etherneteurope.com ] in Munich, Germany on April 17 and 18 at the Hilton Munich Park Hotel. This year's event is collocated with the Metro Ethernet Forum's Quarterly Meeting, making the conference one of the most compelling and productive ...
Phase-III-Studie mit Regorafenib bei Patienten mit metastasiertem GIST erreicht primären Endpunkt
2012-04-03 12:03:42
Statistisch signifikante Verlängerung der progressionsfreien Überlebenszeit
Nicht für US- und UK-Medien bestimmt: Gastrointestinale Stroma-Tumoren (GIST)
Berlin, 3. April 2012 - Die klinische Phase-III-Studie GRID (GIST - Regorafenib In Progressive Disease) mit dem Entwicklungspräparat Regorafenib (BAY 73-4506) von Bayer hat positive Ergebnisse erzielt und den primären Endpunkt - eine ...
Knorr-Bremse delivers growth of more than 500 million euros
2012-03-28 12:05:20
München (ots) -
- Sales: 4.24 bn. EUR (previous year: 3.71 bn. EUR) - Incoming orders: 4.07 bn. EUR (previous year: 4.04 bn. EUR) - Net income: 329 mn. EUR (previous year: 239 mn. EUR) - All regions above 1 bn. EUR in revenues for first time
Knorr-Bremse Group
The Knorr-Bremse Group increased sales during the 2011 fiscal year by more than one-half billion euros (14%) to 4.24 bn. EUR (previous ...
2012-03-16 12:10:20
Minneapolis And Geneva (ots/PRNewswire) -
Milestone comes 25 years after the first DBS implant for Tremor carried out in Grenoble, France
Medtronic, Inc.
today announced that a patient from Kempenhaeghe-Heeze (The Netherlands) is the first patient to be enrolled into the MORE (MedtrOnic Registry for Epilepsy) Registry which is designed to look at the long-term efficacy, quality of life impact ...
Informex Announces Expanded 3rd Annual Specialty Chemical Forum in Houston, TX
2012-03-13 12:06:06
Houston, Texas (ots/PRNewswire) -
June 27-28, 2012 at the Renaissance Houston Greenway Plaza Hotel
Informex is announcing the revamped and restructured conference program for the 3rd Annual Specialty Chemical Forum being held in Houston, Texas on June 27-28, 2012. As North America's only conference and networking event designed specifically for the specialty chemical market, the 2012 program ...
apceth and Indivumed to Develop Biomarker Platform for Targeted Cellular Therapies
2012-02-22 12:08:58
Hamburg/Munich (ots) - apceth GmbH & Co. KG, located in Munich, Germany, and Indivumed GmbH, based in Hamburg, Germany, have entered into a partnership for the development of a predominantly tissue-based biomarker strategy for the treatment of solid cancers with cellular and / or gene therapeutics. The goal is to predict the response of a targeted cellular / gene therapy in different cancer types ...
Fujifilm to launch Astalift skincare range in Europe, starting in France
2012-02-11 12:04:02
Astalift to Reveal Skin’s Inner Light
Since the 1930s, luminous skin has captivated and inspired painters, photographers and film producers alike, using light alone to reveal the beauty of the skin. In its pursuit of luminous skin, Fujifilm is to launch the Astalift skincare range into the Europe, starting from March 2012. Astalift is a premium anti-ageing skincare brand developed using ...
2012-02-07 12:12:07
Freising, Germany (ots) - Pieris AG announced today the receipt of a EUR 1 million grant to support the development of the company's proprietary PRS-110 compound targeting c-Met, a cellular receptor that plays a key role in cancer cell growth and metastasis.
The goal of the funded research will be to delineate a biomarker strategy for early clinical development and to aid in the progression of a ...
Monext's Entire Line of Merchant Services PCI DSS Certified
2012-02-01 12:04:19
AIX- EN-PROVENCE, France, January 31, 2012 (ots/PRNewswire) -
Following the certification of its call centre and international acquiring platform, Monext's Payline and Pavavenue services, which are targeted to merchants, have renewed their PCI DSS certification. Monext's tokenisation service (card identification encryption) has also been certified for the first time. This certification ...
2012-01-26 12:04:15
Burscheid, Germany (ots) -
- Cross reference: Pictures are available at http://www.presseportal.de/galerie.htx?type=obs -
Johnson Controls, a global leader in automotive seating, overhead systems, door and instrument panels, and interior electronics, has developed an ...2012-01-25 12:06:37
Burscheid, Germany (ots) -
- Cross reference: Pictures are available at http://www.presseportal.de/galerie.htx?type=obs -
Johnson Controls, a global leader in automotive seating, overhead systems, door and instrument panels, and interior electronics, has developed an ...2012-01-24 12:05:00
Burscheid, Germany (ots) -
- Cross reference: Pictures are available at http://www.presseportal.de/galerie.htx?type=obs -
Johnson Controls, a global leader in automotive seating, overhead systems, door and instrument panels, and interior electronics, has developed an ...2012-01-23 12:11:37
Burscheid, Germany (ots) -
- Cross reference: Pictures are available at http://www.presseportal.de/galerie.htx?type=obs -
Johnson Controls, a global leader in automotive seating, overhead systems, door and instrument panels, and interior electronics, has developed an ...2012-01-23 12:06:17
Burscheid, Germany (ots) -
- Cross reference: Pictures are available at http://www.presseportal.de/galerie.htx?type=obs -
Johnson Controls, a global leader in automotive seating, overhead systems, door and instrument panels, and interior electronics, has developed an ...2012-01-18 12:06:35
Stuttgart/München (ots) - Die aktuellen "Deloitte TMT Predictions 2012" zeigen maßgebliche Trends und Entwicklungen in Technologie, Medien und Telekommunikation (TMT): Fernsehen völlig unabhängig von festen Programmvorgaben und -abläufen kommt bei den meisten Zuschauern nicht gut an. Im Gegenteil: Das Fernsehprogramm ist für viele eine willkommene Strukturierung, dennoch verlagert ...
Brainlab's ExacTrac® System Achieves Major Sales Milestone
2012-01-12 12:11:58
Munich (ots/PRNewswire) -
500th worldwide sale highlights healthcare providers continued focus on
improving care with frameless radiosurgery
Today Brainlab announced the 500th sale of its ExacTrac(R) patient positioning system for frameless radiosurgery. The scale of uptake highlights physicians continued focus on adopting clinically proven systems for high-precision cancer treatments and ...
WISeKey and The Bancorp, Inc. to Form a Joint Venture (WISeCorp.CO) to Change the Way the World Pays
2011-12-14 12:06:19
Geneva, Switzerland and Wilmington, DE (ots) - WISeKey and The Bancorp, Inc. ("Bancorp") (Nasdaq: TBBK) have signed a memorandum of understanding to establish a joint venture to deploy and secure financial services internationally via the WISeID platform (http://www.wiseid.mobi). Bancorp and WISeKey reached an agreement that would result in the integration of WISeKey's Digital Identity Management ...
Project financing for offshore wind farm EnBW Baltic 1 structured and completed
2011-12-05 12:04:31
Frankfurt am Main (ots) -
- Mandated lead arrangers: EIB, KfW IPEX-Bank, LBBW and NIBC Bank N.V. - Debt capital financing amounting to EUR 138 million - Renewable power from the Baltic Sea for 50,000 households
Already since May 2011 the wind farm EnBW Baltic 1 has been delivering green power from the Baltic Sea - since Friday its long-term financing is also in place: a banking syndicate ...
2011-11-15 12:07:07
San Francisco, California (ots) -
--Results Establish Safety, Tolerability, Lack of Immunogenicity and PK/PD Profile for First Anticalin in a Clinical Setting--
Pieris AG presented the results of the Company?s first clinical evaluation of its most advanced Anticalin®, PRS-050, an anti-VEGF targeted protein therapeutic, at the 2011 AACR-NCI-EORTC International Conference held in San Francisco, ...
CeBIT 2012 (Tuesday 6 to Saturday 10 March): CeBIT Global Conferences 2012: first speakers on board
2011-10-26 12:05:36
Hannover (ots) -
- Leading figures from the international digital world - Speakers from Amazon, eBay, IBM, Microsoft, SEC, eMeter, Rovio and more
CeBIT's organizers have already secured the first of many high-profile guest speakers for the CeBIT Global Conferences 2012. CGC features leading figures from the international digital world and is the No. 1 conference event for the global ICT ...
2011-10-19 12:09:18
Freising (ots) - In concert with the award of the EU FP7 Grant to the Pieris-led EUROCALIN Consortium that will enable initial clinical development of Pieris' proprietary hepcidin antagonist program, the company announced today the positive strategic impact of the grant funding on its proprietary Anticalin pipeline.
Currently, the company's most advanced compound has completed a Phase I clinical ...
Aufsichtsratschef von Nokia Siemens Networks ernannt
2011-09-29 12:03:25
Nokia und Siemens stellen jeweils 500 Millionen Euro neues Kapital zur Verfügung
Nokia und Siemens haben heute die Ernennung von Jesper Ovesen zum Vorsitzenden des Aufsichtsrats (Executive Chairman) von Nokia Siemens Networks bekannt gegeben. Die Ernennung tritt heute in Kraft. Als hauptamtlich tätiger Aufsichtsratschef wird Ovesen insbe-sondere die strategische Richtung von Nokia Siemens ...
.